9 results about "Apolipoproteins A" patented technology

The invention provides a cardiac targeting nano drug delivery carrier based on recombinant apolipoprotein, a system, a preparation method and application. The cardiac targeting nano drug delivery carrier comprises a nano carrier core and a functional layer covalently coupled to the surface of the nano carrier core, the nano carrier core comprises an amphiphilic copolymer formed by polylactic acid-glycolic acid and polyethylene glycol; the functional layer comprises recombinant apolipoprotein A-I and heart targeting peptide; the recombinant apolipoprotein A-I contains mutation sites E191A and F225W, and the recombinant apolipoprotein A-I contains mutation sites F225W; the amino acid sequence of the recombinant apolipoprotein A-I is as shown in SEQ ID NO: 1. The cardiac targeting nano drug delivery system based on the recombinant apolipoprotein has the functions of long circulation, cardiac targeting and coordinated regulation and control of metabolism and inflammation, and can be used for precise treatment of chronic heart failure.

The application belongs to the technical field of biological detection, and particularly relates to the use of apolipoprotein A-I in the preparation of a diagnostic reagent or system for predicting the risk of severe acute hepatitis E. The application first discloses and verifies the significant correlation between the serum apolipoprotein A-I (apoA-I) level and the adverse clinical outcomes (including severe jaundice, liver failure and death) of patients with acute hepatitis E, and establishes the risk interpretation threshold (0.675 g / L and 0.435 g / L) with clinical practical value. The application can objectively and early identify high-risk patients, and provides a powerful auxiliary tool for clinical stratified management and resource optimization.

The invention discloses a novel application of emodin and a high-density lipoprotein analogue in preparation of a medicine. The high-density lipoprotein analogue comprises apolipoprotein A-1 single mimetic peptide and natural phospholipid. The invention has the advantages of long-term stability and no immunogenicity and organ toxicity risk, thereby providing a clinically convertible solution for precise treatment of nerve injury.

Aspects of the technology relate to a composition comprising: (i) a first RNAi agent that targets Proprotein convertase subtilisin / kexin type 9 (PCSK9) and a second RNAi agent that targets angiotensinogen (AGT); (ii) a first RNAi agent that targets PCSK9 and a third RNAi agent that targets Apolipoprotein A (LPA); (iii) a second RNAi agent that targets AGT and a third RNAI agent that targets LPA, or (iv) a first RNAi agent that targets PCSK9, a second RNAi agent that targets AGT, and the third RNAi agent that targets LPA.

The invention relates to the field of medicine, in particular to experimental pharmacology, and can be used for preparing a pharmaceutical composition and a dosage form for treating craniocerebral injury. In order to expand the reserve of treatment means for craniocerebral injury, the invention provides application of human apolipoprotein A-I or functional important fragments thereof, and the means comprise natural apolipoprotein A-I (extracted from human serum) extracted from human serum, and functional fragments of recombinant human apolipoprotein A-I or human ApoA-I. The functional fragment ApoA-I has a human ApoA-I amino acid sequence truncated from an N terminal, and specifically, the human ApoA-I amino acid sequence has two amino acid residues (amino acid residues 3-243) truncated from the N terminal. The preparation is prepared in the form of a pharmaceutical composition, and comprises human serum lipoprotein AI or a functional fragment thereof and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is water for injection or normal saline. A method of treating craniocerebral injury comprises administering the formulation to a patient in need of treatment in a therapeutically effective dose in a topical or parenteral administration manner.

Disclosed herein, are peptides or fragments thereof capable of binding to oxidized lipids, lipid hydroperoxides or lipopolysaccharides, and a pharmaceutical composition containing the peptides or fragments and methods of using to enhance plasma anti-oxidant PON-1 activity, reduce the risk or ameliorating symptoms of a lipid-mediated inflammatory disease or treat a lipid disorder.

The invention relates to application of apolipoprotein ApApoD2 in regulation and control of pea aphid lipid synthesis, the research finds that the ApApoD2 is specifically expressed in the epidermis of pea aphid, and after the ApApoD2 gene is effectively silenced by injecting the dsRNA of the ApApoD2, the epidermis lipid coating of the ApApoD2 gene is obviously reduced, the drying tolerance of the ApApoD2 gene is obviously reduced, and the apolipoprotein ApApoD2 can be applied to regulation and control of pea aphid lipid synthesis. By combining transcriptome and non-targeted metabolome analysis, it is found that the ApApoD2 gene regulates horny layer lipid synthesis of the pea aphid and accumulation of various nutrient substances, and the apApoD2 gene is very important for maintaining the lipid homeostasis of the body wall. By inhibiting the expression of the ApApoD2 gene, the lipid synthesis of the pea aphid can be effectively inhibited, so that the drying tolerance of the pea aphid is remarkably reduced, and a new thought and a new method are provided for green prevention and treatment of the pea aphid.

The present application relates to the biomedical field, and particularly to a clinical marker for monitoring CRS progress after CAR-T treatment and application thereof, the cytokine release syndrome (CRS) progress is judged by the expression of apolipoprotein A-1, so that effective treatment can be carried out and new treatment methods can be developed. The present application discloses APOA1 for the first time to monitor the cytokine release syndrome (CRS) progress after CAT-T treatment, and it is found through mass spectrometry and biochemical detection that APOA1 is expressed the lowest when the inflammation of the cytokine release syndrome (CRS) patient is the most serious, and with the recovery of the inflammation, its expression is also gradually recovered to the pre-treatment, and the cytokine release syndrome (CRS) progress of the patient has good consistency. These results suggest that APOA1 is an important clinical indicator for monitoring the cytokine release syndrome (CRS).

The invention relates to the technical field of biomedicine nanotechnologies, and discloses degreasing nanoparticles simulating a high-density lipoprotein structure and a preparation method thereof.The nanoparticles are formed by assembling human recombinant apolipoprotein A-I and 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphorylcholine according to the molar ratio of 90: 1-120: 1. The method comprises the following steps: incubating apolipoprotein in a polyethylene glycol molecule crowded environment to induce dominant conformation; constructing a phospholipid-supercritical carbon dioxide system, pumping protein liquid, and realizing instant self-assembly by utilizing a synergistic effect of ultrasonic cavitation and rapid pressure relief expansion; and finally, carrying out tangential flow ultrafiltration purification through a polyethersulfone membrane subjected to surface grafting hydrophilic modification. According to the process, protein aggregation and inactivation are effectively avoided, the problem of membrane pollution is solved, and the assembly efficiency, the particle size uniformity, the degreasing biological activity and the product yield of the nanoparticles are improved.